Trial reportJournal of anesthesia2022
Remimazolam decreased the incidence of early postoperative nausea and vomiting compared to desflurane after laparoscopic gynecological surgery.
Trial report in Journal of anesthesia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 4 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Efficacy of remimazolam in preventing postoperative nausea and vomiting: a systematic review and meta-analysis.Scientific reports · 2025Pooled it
- Comparing the safety and efficacy of remimazolam-based total intravenous anesthesia versus volatile agent-based anesthesia: a meta-analysis of randomized controlled trials.Korean journal of anesthesiology · 2025Pooled it
- Effect of remimazolam for general anesthesia on postoperative nausea and vomiting : A systematic review and meta-analysis.Die Anaesthesiologie · 2024Pooled it
- The use of remimazolamFrontiers in pharmacology · 2023Pooled it
- Remimazolam versus sevoflurane for maintenance of anesthesia and postoperative nausea and vomiting in laparoscopic gynecologic oncology surgery: a randomized controlled trial.BMC anesthesiology · 2026Trial
- Esketamine relieves postoperative depression and pain indicators in patients undergoing laparoscopic total hysterectomy.BMC anesthesiology · 2025Trial
- Efficacy of intraoperative low-dose remimazolam as a third antiemetic agent for preventing early postoperative nausea in high-risk patient: A Randomized controlled trial.BMC anesthesiology · 2025Trial
- Effects of Esketamine Combined With Remimazolam Tosylate on Hemodynamics During Cardiovascular Anesthesia.Clinical and translational science · 2025Trial
- Determining the 90% Effective Dose of Remimazolam to Prevent Physical Movement in Surgical Abortions: A Biased-Coin Up-and-Down Sequential Allocation Trial.Drug design, development and therapy · 2025Trial
- Comparison of remimazolam and midazolam for preventing intraoperative nausea and vomiting during cesarean section under spinal anesthesia: a randomized controlled trial.Korean journal of anesthesiology · 2024Trial
- The incidences of nausea and vomiting after general anesthesia with remimazolam versus sevoflurane: a prospective randomized controlled trial.Korean journal of anesthesiology · 2024Trial
- Effect of S-Ketamine on Postoperative Nausea and Vomiting in Patients Undergoing Video-Assisted Thoracic Surgery: A Randomized Controlled Trial.Drug design, development and therapy · 2024Trial
- Impact of Remimazolam versus Sevoflurane Anesthesia on Cerebral Oxygenation and Intracranial Pressure during Gynecological Laparoscopy with Mild Hypercapnia.Medical science monitor : international medical journal of experimental and clinical research · 2023Trial
- Remimazolam-remifentanil causes less postoperative nausea and vomiting than remimazolam-alfentanil during hysteroscopy: a single-centre randomized controlled trial.BMC anesthesiology · 2023Trial
- Comparison of postoperative nausea and vomiting between Remimazolam and Propofol in Patients undergoing oral and maxillofacial surgery: a prospective Randomized Controlled Trial.BMC anesthesiology · 2023Trial
- Effect of Remimazolam on Postoperative Delirium in Older Adult Patients Undergoing Orthopedic Surgery: A Prospective Randomized Controlled Clinical Trial.Drug design, development and therapy · 2023Trial
- Prevention of postoperative nausea and vomiting after gynaecological day surgery under remimazolam general anesthesia: a randomized double-blind controlled study.BMC anesthesiology · 2022Trial
- Remimazolam vs. propofol for prevention of postoperative nausea and vomiting in laparoscopic gynecological surgery: a randomized non-inferiority trial.Perioperative medicine (London, England) · 2026Article
- Target-Controlled Infusion with PSI- and ANI-Guided Sufentanil Versus Remifentanil in Remimazolam-Based Total Intravenous Anesthesia for Postoperative Analgesia and Recovery After Laparoscopic Subtotal Gastrectomy: A Randomized Controlled Study.Journal of clinical medicine · 2025Article
- Anesthetic Management Using Remimazolam for Dental Treatment in a Pediatric Patient With Dravet Syndrome.Anesthesia progress · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePostoperative nausea and vomiting (PONV) is a common adverse event after surgery. Remimazolam is a novel sedative agent recently approved for general anesthesia in Japan. This study evaluated the efficacy of remimazolam in the incidence of PONV after laparoscopic gynecological surgery under general anesthesia.
methodsThis prospective, randomized controlled trial included 64 women who underwent laparoscopic gynecological surgery. The patients were randomly assigned to undergo general anesthesia with either remimazolam (REM group) or desflurane (DES group, n = 30, each group). The primary outcome was the incidence of PONV in the two groups at 2 h and 24 h after the surgery. The incidence of vomiting, rescue antiemetic use, and severity of nausea were also evaluated.
resultsIn the REM group, the incidence of PONV (27% versus 60%, respectively; P = 0.02), rescue antiemetic use (0 versus 7, respectively; P = 0.01), and nausea score (P = 0.01) were significantly decreased during the first 2 h after surgery. No parameters were significantly different 24 h after surgery between the two groups.
conclusionRemimazolam can reduce the incidence of PONV after laparoscopic gynecological surgery compared to general anesthesia with desflurane during the early postoperative period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.